Arecor Therapeutics PLC Arecor wins at CambridgeshireLive Business Awards
28 March 2022 - 5:01PM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
28 March 2022
ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE
YEAR AWARDS
AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS
Cambridge, UK, 28 March 2022: Arecor Therapeutics plc (AIM:
AREC) , the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that Arecor has won the HCR
Hewitsons Award for Innovation in Business, and CEO, Sarah Howell,
has won Business Person of the Year at the UK CambridgeshireLive
Business Awards.
The CambridgeshireLive Business Awards celebrate and recognise
the region's best business talent, providing companies of all
sizes, from pioneering start-ups to the powerhouses which drive the
region's economy a chance to be recognised and be proud of their
achievements.
Sarah Howell, Chief Executive Officer of Arecor, said: "We are
delighted to have won the Award for Innovation in Business, and I
am honoured to be recognised amongst such high-quality candidates
leading innovative and dynamic companies in Cambridge. Innovation
is at the heart of everything we do here at Arecor as we develop
new advanced medicines from today's therapies to improve the lives
of patients. These awards are an important external validation of
Arecor's strengths and will support us to attract scientific talent
to our growing business."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAXDSADDAEFA
(END) Dow Jones Newswires
March 28, 2022 02:01 ET (06:01 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024